Public spending on healthcare has risen dramatically in the United States from just under 50% of total healthcare spending in 2013 to 81-82% of total healthcare spending in 2014-2016.
Despite political and social unrest percolating in parts of the region, the Middle East pharmaceutical market is experiencing strong growth. With government policies and investments supporting the growing healthcare infrastructure, multinational companies are seeing keen opportunities to tap into the region’s economic potential.
The global COVID-19 pandemic brought to the forefront the critical importance of healthcare-and the healthcare industry-in ways not seen for generations.
Despite the emergence of risk-sharing agreements and prevalence of discounting, international reference pricing (IRP) remains at the center of pharmaceutical price controls across many countries worldwide.
An economic model was constructed to estimate the impact of passing through a share of negotiated manufacturer rebates to patients with commercial insurance at the point of sale (POS).
Diabetes is one of the most prevalent and expensive medical conditions in the U.S. Today, nearly half of adults in the U.S.
Diabetes imposes a significant economic burden on Medicare, at a cost of more than $100 billion annually.